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doi:10.1016/j.jtcvs.2005.11.012nfractionated heparin was first used in 1953 for cardiac surgery employing
cardiopulmonary bypass (CPB)1 and has remained the standard anticoag-
ulant ever since. This near-monopoly status should not imply ideal drug
roperties. Indeed, heparin has several disadvantages: it poorly inhibits fibrin-bound
hrombin, and thus thrombin is generated progressively during CPB; its thrombin
nhibition is only indirect (via antithrombin) and leads to antithrombin depletion,
ith potential for adverse consequences2; and its monitoring (by activated clotting
ime [ACT]) only roughly estimates anticoagulant effect. Moreover, heparin’s
ntidote, protamine, is itself problematic: its shorter half-life can lead to bleeding
via protamine “rebound”) and its foreign structure can trigger life-threatening
ypersensitivity reactions.
A largely unexplored issue is whether heparin’s large size and strong negative
harge, which result in binding to many proteins, are responsible for certain adverse
vents associated with CPB. Indeed, one protein to which heparin binds is a
ositively charged chemokine, platelet factor 4 (PF4). The resulting complexes of
F4 and heparin are very immunogenic: detectable antibodies against PF4/heparin
omplexes develop in as many as 70% of patients after heparin exposure during
PB.3 In 1% to 3% of patients, the levels of these antibodies are sufficiently great,
nd their platelet-activating properties sufficiently pathologic, that if the patient
ontinues to receive heparin for a week or more after cardiac surgery, immune
eparin-induced thrombocytopenia (HIT) results, with high risk for the development
f venous or arterial thrombosis.4 In a few patients, HIT results even if postoperative
eparin is not given, because of the autoimmune-like platelet-activating properties
f these unusually pathologic HIT antibodies.5
A largely anecdotal experience has developed with alternative nonheparin anti-
oagulants for patients requiring CPB in whom heparin is considered absolutely or
elatively contraindicated because of acute or previous HIT. These agents include
he heparinoid, danaparoid, and the direct thrombin inhibitors, lepirudin and ar-
atroban.4 The largest patient series involved danaparoid6 and lepirudin.7 Although
any patients had satisfactory outcomes, problems such as excess bleeding and drug
ccumulation in the renally compromised patient have limited their use beyond HIT.
one of these agents has been compared systematically with heparin for routine
PB anticoagulation.
At least, this was the situation until the arrival of bivalirudin. This “hirulog”
analog of hirudin) possesses a relatively short half-life (25-30 minutes) and exhibits
redominant nonorgan metabolism via proteolysis.8 Thus, significant drug clearance
ccurs even despite dual renal and hepatic compromise. However, this feature also
epresents a potential limitation: new drug must be constantly infused to maintain
nticoagulation, as stagnant bivalirudin-anticoagulated blood will eventually throm-
ose, with implications for clotting within the CPB circuit and reservoir and for
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Lanaging blood cardioplegia. Thus, the perfusionist, car-
iac anesthesiologist, and cardiac surgeon need to adapt
heir techniques and procedures to the properties of this
gent.8
Previously, bivalirudin compared favorably with hep-
rin/protamine in a randomized trial for anticoagulation
uring “off-pump” cardiac surgery and was associated with
 significantly lower rate of graft occlusion.9 In this issue of
his Journal, Dyke and colleagues10 report the results of a
:1 randomized trial comparing bivalirudin (n  98) versus
eparin/protamine (n  52) for “on-pump” anticoagulation.
he bivalirudin dosing schedule (bolus: 1 mg/kg [plus 50
g in pump prime]; infusion: 2.5 mg · kg1 · h1 [to main-
ain ACT 2.5 times baseline]) is approximately 30%
reater than when used for off-pump surgery. The results
uggest that bivalirudin could emerge as the first serious
andidate to displace heparin from its half-century domi-
ance in the cardiac operating suite.
In this small trial, no significant difference in the primary
nd point of procedural success (absence of death, non–Q-
ave myocardial infarction (MI), stroke, repeat coronary
evascularization) was seen: bivalirudin, 94.8% vs heparin,
2.2% (12-week follow-up). There was greater early post-
perative blood loss with bivalirudin (median at 2 hours,
38 vs 160 mL; P  .0009) and numerically higher rate of
eoperation for bleeding (5.1% vs 1.9%; P  .67), but an
ffsetting tendency to less perioperative non–Q-wave MI
5.1% vs 9.6%; P  .32). Potentially, the greater ability of
ivalirudin to inhibit fibrin-bound thrombin compared with
eparin might be advantageous in reducing risk of CPB-
ssociated thrombosis.
What subsequent data could promote widespread adop-
ion of bivalirudin anticoagulation for CPB? Larger studies
hat establish comparable safety of bivalirudin and that
upport at least one major clinically relevant advantage over
eparin/protamine would likely be needed. Important such
nd points could include reduced postoperative MI or stroke,
educed bleeding, or, as suggested by the off-pump trial,9
16 The Journal of Thoracic and Cardiovascular Surgery ● Marcmproved long-term graft patency. From the perspective of
he cardiac surgeon, anesthesiologist, and perfusionist, there
ust exist both the perception and reality that intraoperative
ivalirudin dosing and monitoring can be safely and easily
anaged. Finally, an important “bivalirudin bonus” that could
ip the balance toward widespread adoption for cardiac
urgery might be avoidance of postoperative HIT (however,
upportive data on formation of platelet-activating anti-PF4/
eparin antibodies were not provided in the current report).
aybe one day changing the way we administer anticoag-
lation during CPB will change the outcomes of cardiac
urgery for the better.
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